Use of in vitro performance models in the assessment of drug delivery across the human nail for nail disorders

References

• U.S. Department of Health and Human Services. U.S. Food and Drug Administration. Patient information for Jublia: FDA drug labels database, 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf [last accessed 2018 Jan 11
   Google Scholar
• U.S. Department of Health and Human Services. U.S. Food and Drug Administration. Patient information for penlac®. FDA drug labels database, 2004. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf [last accessed 2018 Jan 11
   Google Scholar
• U.S. Department of Health and Human Services. U.S. Food and Drug Administration. Patient information for kerydin®. FDA drug labels database, 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf [last accessed 2018 Jan 25
   Google Scholar
• Draft Guidance on Ciclopirox. FDA guidance information, 2011. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm199631.pdf [last accessed 2018 Jan 25
   Google Scholar
• Kobayashi Y, Miyamoto M, Sugibayashi K, et al. Drug permeation through the three layers of the human nail plate. J Pharm Pharmacol. 1999;51:271–278.
   PubMed Web of Science ®Google Scholar
• Walters KA, Flynn GL, Marvel JR. Physicochemical characterization of the human nail: permeation pattern for water and the homologous alcohols and differences with respect to the stratum corneum. J Pharm Pharmacol. 1983;35:28–33.
   PubMed Web of Science ®Google Scholar
• Khengar RH, Jones SA, Turner RB, et al. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm Res. 2007;24:2207–2212.
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Agner T, Serup J. Transonychial waterloss: relation to sex, age and nail-plate thickness. Br J Dermatol. 1989;121:443–446.
   PubMed Web of Science ®Google Scholar
• Walters KA, Flynn GL, Marvel JR. Physicochemical characterization of the human nail: solvent effects on the permeation of homologous alcohols. J Pharm Pharmacol. 1985;37:771–775.
   PubMed Web of Science ®Google Scholar
• Mertin D, Lippold BC. In vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficiency. J Pharm Pharmacol. 1997;49:866–872.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Komatsu T, Sumi M, et al. In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci. 2004;21:471–477.
   PubMed Web of Science ®Google Scholar
• Hawksworth DL. The magnitude of fungal diversity: the 1–5 million species estimate revisited. Mycol Res. 2001;105(12):1422–1432.
   Google Scholar
• Blackwell M. The fungi: 1, 2, 3 … 5.1 million species? Am J Bot. 2011;98(3):426–438.
   PubMed Web of Science ®Google Scholar
• Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol. 1993;129(2):101–109.
   PubMed Web of Science ®Google Scholar
• Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol. 1995;133(5):699–703.
   PubMed Web of Science ®Google Scholar
• Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992;126(Suppl 39):23–27.
   PubMedGoogle Scholar
• Sais G, Jucglà A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: A cross-sectional study. Br J Dermatol. 1995;132(5):758–761.
   PubMed Web of Science ®Google Scholar
• Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–770.
   PubMed Web of Science ®Google Scholar
• Saner MV, Kulkarni AD, Pardeshi CV. Insights into drug delivery across the nail plate barrier. J Drug Target. 2014;22(9):769–789.
   PubMed Web of Science ®Google Scholar
• Blank H, Roth FJ Jr. The treatment of dermatomycoses with orally administered griseofulvin. AMA Arch Derm. 1959;79(3):259–266.
   PubMedGoogle Scholar
• van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol. 1992;126(Suppl 39):36–39.
   PubMedGoogle Scholar
• Gupta AK, Cooper EA, Paquet M. Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. J Cutan Med Surg. 2013;17(3):201–206.
   PubMed Web of Science ®Google Scholar
• Piraccini BM, Alessandrini A. Onychomycosis: a review. J Fungi. 2015;1:30–43.
   Google Scholar
• British Journal of Dermatology. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Available at: https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.13358 [last accessed 2018 May 15
   Google Scholar
• Shirwaikar AA, Thomas T, Shirwaikar A, et al. Treatment of onychomycosis: an update. Indian J Pharm Sci. 2008;70(6):710–714.
   PubMed Web of Science ®Google Scholar
• Ajit C, Suvannasankha A, Zaeri N, et al. Terbinafine-associated hepatotoxicity. Am J Med Sci. 2003;325(5):292–527.
   PubMed Web of Science ®Google Scholar
• Chambers WM, Millar A, Jain S, et al. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol. 2001;13(9):1115–1118.
   PubMed Web of Science ®Google Scholar
• Rodriguez DA.Efinaconazole Topical Solution. 10%, for the treatment of mild and moderate toenail onychomycosis. J Clin Aesthet Dermatol. 2015;8(6):24–29.
   Google Scholar
• Queller JN, Bhatia N. The dermatologist’s approach to onychomycosis. J Fungi. 2015;1:173–18430.
   Google Scholar
• Akomeah FK, Martin GP, Brown MB. Variability in human skin permeability in vitro: comparing penetrants with different physicochemical properties. J Pharm Sci. 2007;96(4):824–834.
   PubMed Web of Science ®Google Scholar
• Brown MB, Martin GP, Jones SA, et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175–187.
   PubMed Web of Science ®Google Scholar
• Brown MB, Traynor MJ, Martin GP, et al. Transdermal drug delivery systems: skin perturbation devices. Methods Mol Bio. 2008;437:119–139.
   PubMedGoogle Scholar
• Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224(1–2):1–18.
   PubMedGoogle Scholar
• Traynor MJ, Turner RB, Evans CR, et al. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents. J Pharm Pharmacol. 2010;62(6):730–737.
   PubMed Web of Science ®Google Scholar
• Hui X, Jung EC, Zhu H, et al. Antifungal ME1111 in vitro human onychopharmacokinetics. Drug Dev Ind Pharm. 2017;43(1):22–29.
   PubMed Web of Science ®Google Scholar
• Kubota-Ishida N, Takei-Masuda N, Kaneda K, et al. In vitro human onychopharmacokinetic and pharmacodynamic analyses of me1111, a new topical agent for onychomycosis. Antimicrob Agents Chemother. 2017;62(1):e00779–17.
   PubMed Web of Science ®Google Scholar
• Christensen L, Turner R, Weaver S, et al. Evaluation of the ability of a novel miconazole formulation to penetrate nail by using three in vitro nail models. Antimicrob Agents Chemother. 2017;61(7):e02554–16.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Vlahovic TC, Foley KA, et al. In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails. J Dermatolog Treat 2018;29(6):633–636.
   Web of Science ®Google Scholar
• Turner R, Weaver S, Caserta F, et al. A novel vehicle for enhanced drug delivery across the human nail for the treatment of onychomycosis. Int J Pharm Compd. 2016;20(1):71–80.
   PubMedGoogle Scholar